戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  induced by the live attenuated yellow fever viral vaccine.
2 ollowing nasal delivery of a live attenuated viral vaccine.
3 CMV NAb were produced after two doses of the viral vaccine.
4 bserved upon vaccination with an inactivated viral vaccine.
5 t an excellent candidate for a modified live viral vaccine.
6 rce of help for driving Ab responses against viral vaccines.
7 ne editing for the development of innovative viral vaccines.
8 d help advance the development of cancer and viral vaccines.
9 ntrol of viral infections and performance of viral vaccines.
10  rational design of conditionally attenuated viral vaccines.
11 IFN-I blockade also improved the efficacy of viral vaccines.
12 glycosylation patterns in developing subunit viral vaccines.
13 platform for creation of live attenuated RNA viral vaccines.
14 ian of 2 months was similar to that of other viral vaccines.
15  of RIG-I ligands as molecular adjuvants for viral vaccines.
16  plausible correlate of attenuation for live viral vaccines.
17 s and, eventually, for other live-attenuated viral vaccines.
18 l for monitoring genetic consistency of live viral vaccines.
19 y were used to examine eight live-attenuated viral vaccines.
20 the current safety record of live-attenuated viral vaccines.
21 pesviral gene therapy vectors and attenuated viral vaccines.
22 y and mortality, despite the availability of viral vaccines.
23  be an attractive alternative to recombinant viral vaccines.
24                     Here, we present a novel viral vaccine adjuvant comprised of two synthetic ligand
25 that FcRn can effectively deliver a trimeric viral vaccine Ag in the respiratory tract and elicit pot
26 hnology for development of a live attenuated viral vaccine against dengue viruses.
27 erimental vaccine as a novel live-attenuated viral vaccine against Japanese encephalitis.
28 or developing antivirals and live-attenuated viral vaccines against deadly arenavirus pathogens.
29 e potential implications for next-generation viral vaccines aimed at directing B cell responses to pr
30 the development of inactivated or attenuated viral vaccines along with subunit vaccines for prophylax
31  rational approach to the generation of live viral vaccines: alteration of virally encoded type I IFN
32 the ZAP antiviral system may allow for novel viral vaccine and anticancer therapy development.
33 ity for improving the safety and efficacy of viral vaccine and oncolytic vectors.
34 tudy of HEV biology is helpful for designing viral vaccines and drugs.
35 ALDI-TOF for routine quality control of live viral vaccines and for assessment of genetic stability a
36 alty applications, such as the production of viral vaccines and gene therapies, reactor technology re
37 ng the safety of chicken RT activity in live viral vaccines and support the continued use of chick-ce
38 on will be key for developing effective anti-viral vaccines and therapies to prevent and treat KSHV i
39 he immune response to concurrent respiratory viral vaccines and, in some cases, improved response.
40  the search for an effective live attenuated viral vaccine, and past trials with inactivated virus pr
41 ine effectiveness is low compared with other viral vaccines, and the induced immune response is narro
42 these vaccines are not as effective as other viral vaccines, and there is clearly room for improvemen
43 he immune system render it exceptional among viral vaccine antigens and hinder its immunogenicity in
44               Although egg-based inactivated viral vaccines are available, their effectiveness depend
45                                         Most viral vaccines are based on inducing neutralizing antibo
46                                      Subunit viral vaccines are typically not as efficient as live at
47 ated YF vaccine is one of the most effective viral vaccines available today.
48 f nanoparticles, including a live attenuated viral vaccine, both in water and in the presence of diff
49 assays for viral particles quantification in viral vaccines by incorporating (i) aptamers, (ii) micro
50    In this study, we compared a single-cycle viral vaccine candidate, which is unique in that it elic
51 ecent experience with developing and testing viral vaccine candidates can inform expectations regardi
52  As a first step in creating live attenuated viral vaccine candidates for this serogroup, we have gen
53 ions for optimizing the development of other viral vaccine candidates.
54  for developing antivirals and/or attenuated viral vaccine candidates.IMPORTANCE Several arenaviruses
55 tive and dominant-negative HSV-1 recombinant viral vaccine, CJ9-gD, for protection against HSV infect
56 , in circumstances of established tolerance, viral vaccines could break CD8 tolerance in the presence
57 ctic and therapeutic modalities and to guide viral vaccine design.
58 n unprecedented achievement for noninfluenza viral vaccine development.
59  protein trafficking, viral replication, and viral vaccine development.
60                   The HA DNA and inactivated viral vaccines elicited similar protection in that initi
61                                         This viral vaccine, expressing gB derived from CMV strain AD1
62 r CoronaVac (Instituto Butantan) inactivated viral vaccine followed by a third dose of mRNA vaccine (
63 eactivation in vivo and may be used to study viral vaccines for their ability to establish latency an
64 ponse in mice immunized with the recombinant viral vaccines fowlpox strain FP9 and modified virus Ank
65                                Most existing viral vaccines generate antibodies that either block ini
66                   We reconstruct and analyse viral vaccine genomes associated with smallpox vaccinati
67                           Development of new viral vaccines has mostly followed this neutralizing ant
68  the possibility of developing peptide-based viral vaccines having broad coverage across MHC haplotyp
69 L-2 complex) enhances the effectiveness of a viral vaccine in a mouse model with known Ag specificity
70               However, the immunogenicity of viral vaccines in older adults is notoriously poor.
71 s of HSV-2 replication-defective recombinant viral vaccines in protection against HSV-2 genital infec
72              Widespread use of bacterial and viral vaccines in young children, including pneumococcal
73 nd its subsequent wider application to other viral vaccines including SARS-CoV-2.
74 insight into mechanisms by which recombinant viral vaccines induce protective immunity via the MyD88-
75 There is considerable interest in developing viral vaccines intended to induce T cell immunity, espec
76 all currently licensed inactivated influenza viral vaccines is assayed by the single radial immunodif
77 ation of immune correlates of protection for viral vaccines is complicated by multiple factors, but t
78 nes.IMPORTANCE The genetic stability of live viral vaccines is important for safety and efficacy.
79         A concern for the development of new viral vaccines is the potential to induce vaccine-enhanc
80 d severe adverse reaction to live attenuated viral vaccines (LAV) and severe viral infections, partic
81 ion, several live attenuated and inactivated viral vaccines manufactured in CCLs were approved after
82 influenza vaccine but not, a live-attenuated viral vaccine, measles vaccine.
83 pairs vaccine efficacy, the effectiveness of viral vaccines might be improved by transient inhibition
84 oaches established for other live attenuated viral vaccines, novel methods to probe virus-host intera
85 etic vaccine systems are less effective than viral vaccines, particularly in cancer systems where epi
86              Although efficacy with multiple viral vaccine platforms has been established in animals,
87 sible, and is similar to that seen for other viral vaccine-preventable diseases.
88 ning GPLN assets to support control of other viral vaccine-preventable, emerging, and reemerging dise
89 y, our data indicate that attenuated or live viral vaccines promote cytokine-induced memory-like NK c
90    Immunization with a killed or inactivated viral vaccine provides significant protection in animals
91                      The development of live viral vaccines relies on empirically derived phenotypic
92 ion of revertants during manufacture of live viral vaccines, requiring rigorous quality control to en
93 eld but also to researchers working in other viral vaccine settings and, critically, to the wider fie
94  case illustrates a circumstance when a live viral vaccine should not be used.
95 y of exploiting the RIG-I pathway to enhance viral-vaccine-specific immunity and have broader implica
96                To achieve rational design of viral-vaccine stabilizers, our approach is aided by simp
97    A disabled infectious single-cycle (DISC) viral vaccine strain based on a guinea pig cytomegalovir
98  of the top candidates dramatically improved viral vaccine strain production.
99           The first comparison of a live RNA viral vaccine strain to its wild-type parental strain by
100 at could be valuable for the construction of viral vaccine strains against human and animal pathogens
101 elopment of antivirals and shaped cancer and viral vaccine strategies.
102                                  Recombinant viral vaccines such as those based on vaccinia or adenov
103 eneric and can also be used to predict other viral vaccine targets.
104 c engineering now enables the design of live viral vaccines that are potentially transmissible.
105 ew light on the development of effective HSV viral vaccines that encode a unique safety mechanism cap
106 .gov was searched to identify trials testing viral vaccines that had not advanced to phase 2 before 2
107 ding DNA adjuvants to inactivated or subunit viral vaccines that, by themselves, provide only partial
108 ample, in quality control of live attenuated viral vaccines, the presence of even small quantities of
109  field crops, either by the application of a viral vaccine to healthy plants, or by the transgenic ex
110 -1) usually require boosting with protein or viral vaccines to achieve optimal efficacy.
111 asures, we aimed at developing a replicating viral vaccine using the highly efficacious measles vacci
112                                  Recombinant viral vaccines using chimpanzee adenovirus 63 (ChAd63) a
113  Thus, recombinant YF viruses are attractive viral vaccine vector candidates for the development of t
114 s a vaccine against monkeypox virus and as a viral vaccine vector.
115  some of the most widely used and successful viral vaccine vectors and is also related to the human p
116 sults contrast with those observed for other viral vaccine vectors and suggest that preexisting immun
117 R ligands can modulate the immunogenicity of viral vaccine vectors both positively and negatively.
118                                              Viral vaccine vectors have emerged as an attractive stra
119 anscriptional competence of live recombinant viral vaccine vectors in the absence of a cold chain.
120 onstrates an important technical advance for viral vaccine vectors progressing to the clinic and prov
121           To enable a new generation of anti-viral vaccines, we designed self-assembling protein nano

 
Page Top